Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08 2023 - 11:46AM
Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage
biotechnology company that is focused on developing novel human
therapies with high fidelity in three-dimensional (3D) human
tissues that recapitulate key aspects of human disease, today
announced that Keith Murphy, Founder and Executive Chairman,
will present a corporate update and hold meetings with
institutional investors during the H.C. Wainwright 25th Annual
Global Investment Conference being held September 11-13, 2023.
Institutional investors interested in arranging
a meeting with management can register to attend the conference
virtually or in-person at the Lotte New York Palace Hotel.
Date: September 11, 2023 Presentation Time:
10:00 a.m. ET Presenter: Keith Murphy
About Organovo
Organovo is a clinical stage biotechnology
company that is developing drugs that are demonstrated to be
effective in three-dimensional (3D) human tissues as candidates for
drug development. The company’s lead molecule, FXR314, is on the
path for Phase 2 investigation in inflammatory bowel disease and
has potential application in metabolic disease and oncology. The
company has proprietary technology used to build 3D human tissues
that mimic key aspects of native human tissue composition,
architecture, function and disease. For more information visit
Organovo's website at www.organovo.com.
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. These risks and
uncertainties and other factors are identified and described in
more detail in the Company’s filings with the SEC, including
its Annual Report on Form 10-K filed with
the SEC on July 14, 2023, as such risk factors are
updated in its most recently filed Quarterly Report on Form 10-Q
filed with the SEC on August 10, 2023. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United
States, the Company does not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
Investor Contact
Amato and Partners, LLCInvestor Relations
Counseladmin@amatoandpartners.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Apr 2024 to May 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From May 2023 to May 2024